» Articles » PMID: 27293957

Parkinson's Disease: The Mitochondria-Iron Link

Overview
Journal Parkinsons Dis
Publisher Wiley
Date 2016 Jun 14
PMID 27293957
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Mitochondrial dysfunction, iron accumulation, and oxidative damage are conditions often found in damaged brain areas of Parkinson's disease. We propose that a causal link exists between these three events. Mitochondrial dysfunction results not only in increased reactive oxygen species production but also in decreased iron-sulfur cluster synthesis and unorthodox activation of Iron Regulatory Protein 1 (IRP1), a key regulator of cell iron homeostasis. In turn, IRP1 activation results in iron accumulation and hydroxyl radical-mediated damage. These three occurrences-mitochondrial dysfunction, iron accumulation, and oxidative damage-generate a positive feedback loop of increased iron accumulation and oxidative stress. Here, we review the evidence that points to a link between mitochondrial dysfunction and iron accumulation as early events in the development of sporadic and genetic cases of Parkinson's disease. Finally, an attempt is done to contextualize the possible relationship between mitochondria dysfunction and iron dyshomeostasis. Based on published evidence, we propose that iron chelation-by decreasing iron-associated oxidative damage and by inducing cell survival and cell-rescue pathways-is a viable therapy for retarding this cycle.

Citing Articles

Iron Accumulation and Lipid Peroxidation in Cellular Models of Nemaline Myopathies.

Lopez-Cabrera A, Pinero-Perez R, Alvarez-Cordoba M, Cilleros-Holgado P, Gomez-Fernandez D, Reche-Lopez D Int J Mol Sci. 2025; 26(4).

PMID: 40003902 PMC: 11855326. DOI: 10.3390/ijms26041434.


Genetic Markers of Postmortem Brain Iron.

Cornelis M, Fazlollahi A, Bennett D, Schneider J, Ayton S J Neurochem. 2025; 169(2):e16309.

PMID: 39918201 PMC: 11804167. DOI: 10.1111/jnc.16309.


Hemochromatosis neural archetype reveals iron disruption in motor circuits.

Loughnan R, Ahern J, Boyle M, Jernigan T, Hagler Jr D, Iversen J Sci Adv. 2024; 10(47):eadp4431.

PMID: 39576859 PMC: 11584016. DOI: 10.1126/sciadv.adp4431.


HMGB1 Mediates Inflammation-Induced DMT1 Increase and Dopaminergic Neurodegeneration in the Early Stage of Parkinsonism.

Liang T, Yang S, Qian C, Du L, Qian Z, Yung W Mol Neurobiol. 2023; 61(4):2006-2020.

PMID: 37833459 DOI: 10.1007/s12035-023-03668-2.


On the Chemical and Biological Characteristics of Multifunctional Compounds for the Treatment of Parkinson's Disease.

Garcia-Beltran O, Urrutia P, Nunez M Antioxidants (Basel). 2023; 12(2).

PMID: 36829773 PMC: 9952574. DOI: 10.3390/antiox12020214.


References
1.
Rappold P, Cui M, Chesser A, Tibbett J, Grima J, Duan L . Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3. Proc Natl Acad Sci U S A. 2011; 108(51):20766-71. PMC: 3251116. DOI: 10.1073/pnas.1115141108. View

2.
Hidalgo C, Nunez M . Calcium, iron and neuronal function. IUBMB Life. 2007; 59(4-5):280-5. DOI: 10.1080/15216540701222906. View

3.
Cadenas E, Davies K . Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med. 2000; 29(3-4):222-30. DOI: 10.1016/s0891-5849(00)00317-8. View

4.
Ben-Shachar D, Eshel G, Finberg J, Youdim M . The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem. 1991; 56(4):1441-4. DOI: 10.1111/j.1471-4159.1991.tb11444.x. View

5.
Gerlach M, Riederer P, Przuntek H, Youdim M . MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol. 1991; 208(4):273-86. DOI: 10.1016/0922-4106(91)90073-q. View